These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38815498)

  • 1. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy.
    Mantri S; Cheng AC; Saia K; Shrestha H; Amgott R; Bressler J; Werler MM; Carter G; Jones HE; Wachman EM
    Early Hum Dev; 2024 Jul; 194():106051. PubMed ID: 38815498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gestational buprenorphine-naloxone exposure and fetal neurobehavior.
    Jansson LM; McConnell K; Velez ML; Spencer N; Milio L; Leoutsakos J; DiPietro JA
    Neurotoxicol Teratol; 2024; 104():107368. PubMed ID: 38906389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
    Debelak K; Morrone WR; O'Grady KE; Jones HE
    Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
    Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J
    Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal buprenorphine exposure and neonatal neurobehavioral functioning.
    Velez ML; McConnell K; Spencer N; Montoya L; Tuten M; Jansson LM
    Early Hum Dev; 2018 Feb; 117():7-14. PubMed ID: 29223912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
    Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
    Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal neurobehavior effects following buprenorphine versus methadone exposure.
    Coyle MG; Salisbury AL; Lester BM; Jones HE; Lin H; Graf-Rohrmeister K; Fischer G
    Addiction; 2012 Nov; 107 Suppl 1(0 1):63-73. PubMed ID: 23106928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.
    Mullins N; Galvin SL; Ramage M; Gannon M; Lorenz K; Sager B; Coulson CC
    J Addict Med; 2020; 14(3):185-192. PubMed ID: 31567599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.
    Kanervo M; Tupola S; Nikkola E; Rantakari K; Kahila H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():106-110. PubMed ID: 38608352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.
    Latif ZE; Solli KK; Opheim A; Kunoe N; Benth JŠ; Krajci P; Sharma-Haase K; Tanum L
    Am J Addict; 2019 Feb; 28(2):77-85. PubMed ID: 30701613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone.
    Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of the newer class of opioid antagonists in pregnancy.
    Poon S; Pupco A; Koren G; Bozzo P
    Can Fam Physician; 2014 Jul; 60(7):631-2, e348-9. PubMed ID: 25022635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine and naloxone compared with methadone treatment in pregnancy.
    Wiegand SL; Stringer EM; Stuebe AM; Jones H; Seashore C; Thorp J
    Obstet Gynecol; 2015 Feb; 125(2):363-368. PubMed ID: 25569005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.
    Link HM; Jones H; Miller L; Kaltenbach K; Seligman N
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100179. PubMed ID: 33345863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
    Morgan JR; Schackman BR; Weinstein ZM; Walley AY; Linas BP
    Drug Alcohol Depend; 2019 Jul; 200():34-39. PubMed ID: 31082666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.